Nevirapina Kern Pharma (Nevirapine)

Nevirapina (nevirapine) is an antiretroviral that targets the HIV‑1 reverse transcriptase enzyme.

• HIV‑1 infection (treatment‑naïve adults): reduces viral load and helps restore immune function.
• HIV‑1 infection (treatment‑experienced adults): provides an alternative regimen when resistance to other agents is present.
• HIV‑1 infection in pediatric patients: used as part of combination therapy to control viral replication.

• Nevirapine binds to a non‑active site of the HIV‑1 reverse transcriptase enzyme, inducing a conformational change that impairs both RNA‑dependent and DNA‑dependent DNA polymerase activities. This inhibition prevents the synthesis of viral DNA, thereby blocking replication of the virus within infected cells.

Nevirapine may cause a range of adverse reactions.

Common Side Effects

• Rash: mild to moderate skin eruption.
• Nausea: occasional gastrointestinal upset.
• Fatigue: feeling of tiredness or weakness.
• Headache: mild to moderate intensity.
• Abdominal pain: discomfort in the stomach area.
• Dizziness: transient sense of light‑headedness.

Serious or Rare Side Effects

• Stevens‑Johnson syndrome or toxic epidermal necrolysis: severe skin reactions requiring immediate discontinuation.
• Hepatic failure: signs of liver injury such as jaundice or elevated enzymes.
• Severe hypersensitivity reactions: including fever, eosinophilia, or organ involvement.
• Neutropenia: marked reduction in white blood cells.
• Severe anemia: significant drop in red blood cell count.
• Life‑threatening rash with mucosal involvement.

Nevirapina requires careful monitoring to minimize risks.

• Liver function monitoring: assess baseline transaminases and repeat periodically during therapy.
• Skin reactions: discontinue immediately if severe rash, Stevens‑Johnson syndrome, or toxic epidermal necrolysis develop.
• Hematologic monitoring: perform regular CBC to detect neutropenia or anemia.
• Drug interactions: avoid concomitant use with potent CYP3A inducers such as rifampicin or St. John's wort.
• Pregnancy and breastfeeding: evaluate risk‑benefit; use only if clearly needed.
• Store at ambient temperature below 25°C: keep in the original pack, protect from moisture and light.

Nevirapina can interact with several medicines, affecting its efficacy or safety.

Major Interactions (Avoid)

• Rifampicin (rifampin): induces metabolism, markedly lowers nevirapine concentrations, risking treatment failure.
• St. John's wort: potent CYP3A4 inducer that may reduce therapeutic effect.
• Carbamazepine: enzyme inducer that decreases nevirapine exposure.

Moderate Interactions (Monitor Closely)

• Protease inhibitors (ritonavir, lopinavir): can increase nevirapine levels, raising risk of toxicity.
• Fluconazole: CYP3A4 inhibitor that may raise nevirapine concentrations.
• Hormonal contraceptives: nevirapine may reduce contraceptive efficacy; consider alternative or additional methods.